Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover

n/

Prednisone treatment of elderly-onset rheumatoid arthritis: Disease activity and bone mass in comparison with chloroquine treatment

Objective. Prednisone is frequently used in the treatment of elderly-onset rheumatoid arthritis (RA), but the balance between efficacy and toxicity, including the effect on bone mass, has not been investigated in long-term studies. This prospective, randomized study was undertaken to compare disease activity and bone mass during long-term treatment with prednisone versus chloroquine in this patient population. Methods. Patients with active RA diagnosed at age ≥ 60 were randomized to receive prednisone (15 mg/day for 1 month, with the dosage tapered as low as possible thereafter) (n = 28) or chloroquine (n = 28). Patients who did not show a response received other second-line drugs as an adjunct to prednisone or as a replacement for chloroquine. Bone mass was measured by dual-energy x-ray absorptiometry. The study duration was 2 years. Results. During the 2 years, treatment with other second-line drugs was needed for 12 patients in the prednisone group (43%) and 8 in the chloroquine group (29%). Functional capacity and disease activity improved significantly in both groups and did not differ significantly between the groups, except for a greater improvement in the prednisone group at 1 month. Radiographic scores for joint destruction progressed similarly in both groups. There was a nonsignificant excess bone loss of 1.8% in the spine and 1.5% in the hip in the prednisone group, compared with the chloroquine group. Conclusion. Neither treatment was entirely satisfactory since a significant number of patients needed an additional second-line drug over the 2-year period

ÁREA DE PRESIDENCIA [Material gráfico]

Forma parte del reportaje fotográfico sobre la inauguración en los años 40 del nuevo edificio institucional del Cabildo de Gran CanariaCopia digital. Madrid : Ministerio de Educación, Cultura y Deporte. Subdirección General de Coordinación Bibliotecaria, 201

From disease to treatment: from rare skeletal disorders to treatments for osteoporosis

Bone and mineral researc

Osteoporosis: An overview

This chapter focuses on the clinical aspects and management of osteoporosis in postmenopausal women, men, young women, and various forms of secondary osteoporosis. Dual energy X‐ray absorptiometry is an important tool for clinical research, including clinical trials of bisphosphonates and other drugs. There is strong consensus, based on solid clinical trial evidence, that postmenopausal women, and probably older men, who have experienced fragility fractures of the spine and hip are definite candidates for pharmacological therapy, irrespective of other risk factors. Patients with nonhip, nonspine fractures are also at higher risk for fracture and deserve, at least, to be evaluated for other risk factors and as potential candidates for therapy. Finite element analysis of routine CT scans of the hip and spine provides accurate in vivo measurement of skeletal strength. The anticipated availability of abaloparatide and romosozumab will be the first new treatments for osteoporosis

Bisphosphonates in osteoporosis—beyond 5 years

Bone and mineral researc